Respiratory syncytial virus infection in adults

Hannah H. Nam, Michael G Ison*

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

Human respiratory syncytial virus (RSV) belongs to the recently defined Pneumoviridae family, Orthopneumovirus genus. It is a negative sense, single stranded RNA virus that results in epidemics of respiratory infections that typically peak in the winter in temperate climates and during the rainy season in tropical climates. Generally, one of the two genotypes (A and B) predominates in a single season, alternating annually, although regional variation occurs. RSV is a cause of disease and death in children, older people, and immunocompromised patients, and its clinical effect on adults admitted to hospital is clarified with expanded use of multiplex molecular assays. Among adults, RSV produces a wide range of clinical symptoms including upper respiratory tract infections, severe lower respiratory tract infections, and exacerbations of underlying disease. Here we discuss the latest evidence on the burden of RSV related disease in adults, especially in those with immunocompromise or other comorbidities. We review current therapeutic and prevention options, as well as those in development.

Original languageEnglish (US)
Article numberl5021
JournalThe BMJ
Volume366
DOIs
StatePublished - Sep 10 2019

Fingerprint

Respiratory Syncytial Virus Infections
Respiratory Syncytial Viruses
Respiratory Tract Infections
Human respiratory syncytial virus
Tropical Climate
RNA Viruses
Immunocompromised Host
Virus Diseases
Climate
Disease Progression
Comorbidity
Cause of Death
Genotype
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{bd376fd86849475aa44841ad0abadcaa,
title = "Respiratory syncytial virus infection in adults",
abstract = "Human respiratory syncytial virus (RSV) belongs to the recently defined Pneumoviridae family, Orthopneumovirus genus. It is a negative sense, single stranded RNA virus that results in epidemics of respiratory infections that typically peak in the winter in temperate climates and during the rainy season in tropical climates. Generally, one of the two genotypes (A and B) predominates in a single season, alternating annually, although regional variation occurs. RSV is a cause of disease and death in children, older people, and immunocompromised patients, and its clinical effect on adults admitted to hospital is clarified with expanded use of multiplex molecular assays. Among adults, RSV produces a wide range of clinical symptoms including upper respiratory tract infections, severe lower respiratory tract infections, and exacerbations of underlying disease. Here we discuss the latest evidence on the burden of RSV related disease in adults, especially in those with immunocompromise or other comorbidities. We review current therapeutic and prevention options, as well as those in development.",
author = "Nam, {Hannah H.} and Ison, {Michael G}",
year = "2019",
month = "9",
day = "10",
doi = "10.1136/bmj.l5021",
language = "English (US)",
volume = "366",
journal = "British Medical Journal",
issn = "0959-8146",
publisher = "BMJ Publishing Group",

}

Respiratory syncytial virus infection in adults. / Nam, Hannah H.; Ison, Michael G.

In: The BMJ, Vol. 366, l5021, 10.09.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Respiratory syncytial virus infection in adults

AU - Nam, Hannah H.

AU - Ison, Michael G

PY - 2019/9/10

Y1 - 2019/9/10

N2 - Human respiratory syncytial virus (RSV) belongs to the recently defined Pneumoviridae family, Orthopneumovirus genus. It is a negative sense, single stranded RNA virus that results in epidemics of respiratory infections that typically peak in the winter in temperate climates and during the rainy season in tropical climates. Generally, one of the two genotypes (A and B) predominates in a single season, alternating annually, although regional variation occurs. RSV is a cause of disease and death in children, older people, and immunocompromised patients, and its clinical effect on adults admitted to hospital is clarified with expanded use of multiplex molecular assays. Among adults, RSV produces a wide range of clinical symptoms including upper respiratory tract infections, severe lower respiratory tract infections, and exacerbations of underlying disease. Here we discuss the latest evidence on the burden of RSV related disease in adults, especially in those with immunocompromise or other comorbidities. We review current therapeutic and prevention options, as well as those in development.

AB - Human respiratory syncytial virus (RSV) belongs to the recently defined Pneumoviridae family, Orthopneumovirus genus. It is a negative sense, single stranded RNA virus that results in epidemics of respiratory infections that typically peak in the winter in temperate climates and during the rainy season in tropical climates. Generally, one of the two genotypes (A and B) predominates in a single season, alternating annually, although regional variation occurs. RSV is a cause of disease and death in children, older people, and immunocompromised patients, and its clinical effect on adults admitted to hospital is clarified with expanded use of multiplex molecular assays. Among adults, RSV produces a wide range of clinical symptoms including upper respiratory tract infections, severe lower respiratory tract infections, and exacerbations of underlying disease. Here we discuss the latest evidence on the burden of RSV related disease in adults, especially in those with immunocompromise or other comorbidities. We review current therapeutic and prevention options, as well as those in development.

UR - http://www.scopus.com/inward/record.url?scp=85072015699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072015699&partnerID=8YFLogxK

U2 - 10.1136/bmj.l5021

DO - 10.1136/bmj.l5021

M3 - Review article

C2 - 31506273

AN - SCOPUS:85072015699

VL - 366

JO - British Medical Journal

JF - British Medical Journal

SN - 0959-8146

M1 - l5021

ER -